Radiopharm Theranostics files AGM notice on Form 6-K

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with a copy of a public notice filed with the Australian Securities Exchange.

Accepted by SEC EDGAR 10/22/2025 - 07:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with a copy of a public notice filed with the Australian Securities Exchange. The attached notice is titled “Notice of Annual General Meeting/Proxy Form,” indicating that the company has called its annual shareholder meeting and circulated related proxy materials in its home market.

The Form 6-K specifies that this information is being furnished, not filed, under U.S. securities laws and will not automatically be incorporated by reference into other U.S. securities filings unless specifically referenced. This keeps U.S. disclosure aligned with the company’s Australian announcements while limiting the legal status of this particular submission.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Radiopharm Theranostics Limited (RADX) report in this Form 6-K?

Radiopharm Theranostics Limited furnished a copy of its Australian Securities Exchange announcement titled “Notice of Annual General Meeting/Proxy Form” as an exhibit to this Form 6-K.

What is the main purpose of this Radiopharm Theranostics (RADX) Form 6-K?

The main purpose is to make the company’s Notice of Annual General Meeting/Proxy Form, published on the Australian Securities Exchange, available to U.S. investors by attaching it as Exhibit 99.1.

Does this Radiopharm Theranostics (RADX) Form 6-K include financial results or earnings data?

No. The Form 6-K only describes and furnishes the Notice of Annual General Meeting/Proxy Form and does not include financial statements, earnings data, or major transaction details.

How is the attached AGM notice treated under U.S. securities law for RADX?

The company states that this Form 6-K, including its exhibit, is furnished and not deemed “filed” under the Exchange Act and will not be incorporated by reference into Securities Act filings unless expressly referenced there.

What document is attached as an exhibit to the Radiopharm Theranostics (RADX) Form 6-K?

The filing lists a single exhibit, Exhibit 99.1, described as the “Notice of Annual General Meeting/Proxy Form.”

Who signed the Radiopharm Theranostics Limited (RADX) Form 6-K?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Phillip Hains, Company Secretary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on October 22, 2025 titled:

“Notice of Annual General Meeting/Proxy Form”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Notice of Annual General Meeting/Proxy Form

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: October 22, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3